CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
CD52 is a small glycopeptide leukocyte antigen present on selected subpopulations of human cells. From the clinical point of view this protein is an important target for therapeutic interventions aimed at leukocyte depletion in hematological malignancies and post-transplant immunosuppression. Recently, two variants of CD52--rs1071849 (A119G; Asn40Ser) and rs17645 (A123G; I1e41Met)--were discovered. We now report on the distribution of these variants in kidney graft recipients and controls. Our bioinformatics findings suggest that CD52 polymorphism may affect the efficiency of GPI anchor formation and thus may indirectly alter the response to anti-CD52 agents.
Oko
Andrzej
A
Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych, Uniwersytetu Medycznego im. Karola Marcinkowskiego ul. Przybyszewskiego 49, 60-355 Poznań.
Wyrwicz
Lucjan S
LS
Glyda
Maciej
M
Idasiak-Piechocka
Ilona
I
Bińczak-Kuleta
Agnieszka
A
Kaczmarczyk
Mariusz
M
Drozd
Arleta
A
Ciechanowicz
Andrzej
A
Czekalski
Stanisław
S
D000074323:Alemtuzumab; D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD / Q000235:genetics*; D000951:Antigens, Neoplasm / Q000235:genetics*; D000074301:CD52 Antigen; D005828:Genetics, Population; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D008969:Molecular Sequence Data; D016366:Open Reading Frames; D010802:Phylogeny; D011044:Poland; D011110:Polymorphism, Genetic; D013045:Species Specificity
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab